X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs VENUS REMEDIES - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON VENUS REMEDIES BIOCON /
VENUS REMEDIES
 
P/E (TTM) x 18.3 -1.0 - View Chart
P/BV x 2.9 0.1 3,966.4% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 BIOCON    VENUS REMEDIES
EQUITY SHARE DATA
    BIOCON
Mar-18
VENUS REMEDIES
Mar-18
BIOCON /
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,188126 943.6%   
Low Rs30561 499.2%   
Sales per share (Unadj.) Rs68.7301.8 22.8%  
Earnings per share (Unadj.) Rs7.6-24.9 -30.4%  
Cash flow per share (Unadj.) Rs14.02.5 549.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.3293.3 29.4%  
Shares outstanding (eoy) m600.0012.34 4,862.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.90.3 3,506.1%   
Avg P/E ratio x98.9-3.8 -2,629.4%  
P/CF ratio (eoy) x53.436.7 145.4%  
Price / Book Value ratio x8.60.3 2,711.8%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,9001,154 38,819.9%   
No. of employees `0006.10.9 664.8%   
Total wages/salary Rs m9,311393 2,368.6%   
Avg. sales/employee Rs Th6,705.84,026.1 166.6%   
Avg. wages/employee Rs Th1,514.2425.0 356.3%   
Avg. net profit/employee Rs Th736.9-331.8 -222.1%   
INCOME DATA
Net Sales Rs m41,2343,724 1,107.2%  
Other income Rs m2,06223 9,164.4%   
Total revenues Rs m43,2963,747 1,155.6%   
Gross profit Rs m8,291395 2,100.1%  
Depreciation Rs m3,851338 1,138.3%   
Interest Rs m615354 173.6%   
Profit before tax Rs m5,887-275 -2,138.4%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,56932 4,965.2%   
Profit after tax Rs m4,531-307 -1,476.4%  
Gross profit margin %20.110.6 189.7%  
Effective tax rate %26.7-11.5 -232.2%   
Net profit margin %11.0-8.2 -133.3%  
BALANCE SHEET DATA
Current assets Rs m41,4862,638 1,572.8%   
Current liabilities Rs m21,4132,305 929.1%   
Net working cap to sales %48.78.9 544.4%  
Current ratio x1.91.1 169.3%  
Inventory Days Days64135 47.2%  
Debtors Days Days9446 203.3%  
Net fixed assets Rs m50,6614,871 1,040.1%   
Share capital Rs m3,000123 2,431.1%   
"Free" reserves Rs m48,8083,496 1,396.2%   
Net worth Rs m51,8083,619 1,431.5%   
Long term debt Rs m17,8981,374 1,302.2%   
Total assets Rs m99,8977,509 1,330.5%  
Interest coverage x10.60.2 4,741.5%   
Debt to equity ratio x0.30.4 91.0%  
Sales to assets ratio x0.40.5 83.2%   
Return on assets %5.20.6 816.0%  
Return on equity %8.7-8.5 -103.1%  
Return on capital %9.61.6 608.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m12,0580-   
Fx outflow Rs m7,348517 1,422.7%   
Net fx Rs m4,710-517 -911.9%   
CASH FLOW
From Operations Rs m6,621514 1,287.1%  
From Investments Rs m-6,840-123 5,556.5%  
From Financial Activity Rs m-2,397-387 619.2%  
Net Cashflow Rs m-2,6124 -62,190.5%  

Share Holding

Indian Promoters % 40.4 32.9 123.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.2 4,666.7%  
FIIs % 10.7 0.6 1,844.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 66.4 30.0%  
Shareholders   109,995 20,121 546.7%  
Pledged promoter(s) holding % 0.0 36.4 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  STERLING BIOTECH  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade on a Flat Note; Oil & Gas and Automobile Stocks Drag(12:30 pm)

Share markets in India are presently trading on a flat note. Sectoral indices are trading mixed with stocks in the oil & gas sector, automobile sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jun 24, 2019 02:11 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS